Your search
Results 3 resources
-
Cardiovascular diseases (CVD) are the leading cause of death worldwide. People affected by CVDs may go undiagnosed until the occurrence of a serious heart failure event such as stroke, heart attack, and myocardial infraction. In Qatar, there is a lack of studies focusing on CVD diagnosis based on non-invasive methods such as retinal image or dual-energy X-ray absorptiometry (DXA). In this study, we aimed at diagnosing CVD using a novel approach integrating information from retinal images and DXA data. We considered an adult Qatari cohort of 500 participants from Qatar Biobank (QBB) with an equal number of participants from the CVD and the control groups. We designed a case-control study with a novel multi-modal (combining data from multiple modalities—DXA and retinal images)—to propose a deep learning (DL)-based technique to distinguish the CVD group from the control group. Uni-modal models based on retinal images and DXA data achieved 75.6% and 77.4% accuracy, respectively. The multi-modal model showed an improved accuracy of 78.3% in classifying CVD group and the control group. We used gradient class activation map (GradCAM) to highlight the areas of interest in the retinal images that influenced the decisions of the proposed DL model most. It was observed that the model focused mostly on the centre of the retinal images where signs of CVD such as hemorrhages were present. This indicates that our model can identify and make use of certain prognosis markers for hypertension and ischemic heart disease. From DXA data, we found higher values for bone mineral density, fat content, muscle mass and bone area across majority of the body parts in CVD group compared to the control group indicating better bone health in the Qatari CVD cohort. This seminal method based on DXA scans and retinal images demonstrate major potentials for the early detection of CVD in a fast and relatively non-invasive manner.
-
Cardiovascular disease (CVD) is reported to be the leading cause of mortality in the middle eastern countries, including Qatar. But no comprehensive study has been conducted on the Qatar specific CVD risk factors identification. The objective of this case-control study was to develop machine learning (ML) model distinguishing healthy individuals from people having CVD, which could ultimately reveal the list of potential risk factors associated to CVD in Qatar. To the best of our knowledge, this study considered the largest collection of biomedical measurements representing the anthropometric measurements, clinical biomarkers, bioimpedance, spirometry, VICORDER readings, and behavioral factors of the CVD group from Qatar Biobank (QBB). CatBoost model achieved 93% accuracy, thereby outperforming the existing model for the same purpose. Interestingly, combining multimodal datasets into the proposed ML model outperformed the ML model built upon currently known risk factors for CVD, emphasizing the importance of incorporating other clinical biomarkers into consideration for CVD diagnosis plan. The ablation study on the multimodal dataset from QBB revealed that physio-clinical and bioimpedance measurements have the most distinguishing power to classify these two groups irrespective of gender and age of the participants. Multiple feature subset selection techniques confirmed known CVD risk factors (blood pressure, lipid profile, smoking, sedentary life, and diabetes), and identified potential novel risk factors linked to CVD-related comorbidities such as renal disorder (e.g., creatinine, uric acid, homocysteine, albumin), atherosclerosis (intima media thickness), hypercoagulable state (fibrinogen), and liver function (e.g., alkaline phosphate, gamma-glutamyl transferase). Moreover, the inclusion of the proposed novel factors into the ML model provides better performance than the model with traditional known risk factors for CVD. The association of the proposed risk factors and comorbidities are required to be investigated in clinical setup to understand their role in CVD better. © 2013 IEEE.
-
Alzheimer's Disease (AD) is a neurodegenerative disease that causes complications with thinking capability, memory and behavior. AD is a major public health problem among the elderly in developed and developing countries. With the growth of AD around the world, there is a need to further expand our understanding of the roles different clinical measurements can have in the diagnosis of AD. In this work, we propose a machine learning-based technique to distinguish control subjects with no cognitive impairments, AD subjects, and subjects with mild cognitive impairment (MCI), often seen as precursors of AD. We utilized several machine learning (ML) techniques and found that Gradient Boosting Decision Trees achieved the highest performance above 84% classification accuracy. Also, we determined the importance of the features (clinical biomarkers) contributing to the proposed multi-class classification system. Further investigation on the biomarkers will pave the way to introduce better treatment plan for AD patients. © 2020 The authors and IOS Press.
Explore
Resource type
- Book Section (1)
- Journal Article (2)